English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe American Society for Radiation Oncology (ASTRO) today announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
Tag: Pfizer
Pfizer-BioNTech and AstraZeneca vaccines offer high protection against severe COVID-19, 6 months after second doses, finds study of over 7 million adults
Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.
Kids and the COVID-19 Vaccine: Eleven Key Questions Answered
With the vaccine for children ages 6 months and older approved, the experts at Children’s Hospital Los Angeles provide guidance for families. The Centers for Disease Control and Prevention (CDC) recommends that everyone approved to receive a COVID-19 vaccine get one—including children ages 6 months and older.
LJI scientists publish first head-to-head comparison of four COVID-19 vaccines
“Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
New Oral Antiviral Drug Reduces Death in Early COVID-19
Researchers note that health care providers are now able to add to their armamentarium against COVID-19 their prescription of this new antiviral drug for high-risk, newly-infected patients as soon as possible following diagnosis or within five days of the onset of symptoms.
Why I’ll Vaccinate My Kids
As the Food and Drug Administration edges closer to emergency use approval of the Pfizer COVID-19 vaccine for children ages 5-11 – which could become available as soon as early November – Rutgers faculty and staff share reasons for why they’ll vaccinate their children.
FDA authorization of COVID-19 vaccine for kids 5 to 11: IU experts available to comment
Following a daylong meeting Oct. 26, the FDA authorized Pfizer’s COVID-19 vaccine for use in children ages 5 to 11. This was the first in a series of meetings to make this vaccine available to younger children. Next, the Advisory…
Expert available to comment on Pfizer’s COVID-19 vaccine for kids
Dr. Ishminder Kaur Dr. Kaur is an assistant professor of pediatrics in the division of infectious diseases at the David Geffen School of Medicine at UCLA and the medical director of the pediatric antimicrobial stewardship program at UCLA Mattel Children’s…
10 questions you want answered on COVID-19
Should children under the age of 12 be vaccinated against COVID-19? Is it possible to achieve herd immunity? Will an 80 per cent vaccination rate keep us safe? In this video, UniSA epidemiologist Professor Adrian Esterman answers these questions and a lot more. The former World Health Organization consultant shares his expertise – 50 years’ worth – and argues for a different approach to tackling COVID-19.
https://www.youtube.com/watch?v=MLKC9q9yEto
Rutgers Pediatric Clinical Trial Experts, Parents Available to Discuss Pfizer’s Vaccine for Children
Rutgers researchers conducting the Pfizer COVID-19 pediatric vaccine clinical trial and parents whose children are participating are available to discuss the recent news of the vaccine prompting a strong immune response in young children.
New study: Nursing home residents, health care workers lose more than 80% of their COVID-19 immunity six months after Pfizer vaccine
A new, multi-institutional study led by Case Western Reserve University—in partnership with Brown University—found that COVID-19 antibodies produced by the Pfizer vaccine decreased sharply in senior nursing home residents and their caregivers six months after receiving their second shots.
Claim that the first COVID-19 vaccine that was approved by the FDA is somehow different than than the “Pfizer vaccine” currently available is misleading
In the podcast and video show “War Room” hosted by Steve Bannon, Dr. Robert Malone claimed that the “mainstream media is lying” and suggested that the vaccine that was approved by the FDA is somehow different than the “Pfizer vaccine” currently available under emergency use authorization.
Rutgers Expert Available to Comment on FDA Approval of Pfizer Vaccine and the Pentagon and NYC’s Vaccine Mandates
Stanley H. Weiss, MD, an epidemiologist and professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health, is available to discuss the impact of the FDA’s approval of the Pfizer/BioNTech Covid-19 vaccine for people age…
Yale Cancer Center Perspective Highlights New Advances for NSCLC
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical research areas to help influence how NSCLC will be managed over the coming decade.
COVID-19 vaccine generates immune structures critical for lasting immunity
A new study from researchers at Washington University School of Medicine in St. Louis, published June 28 in the journal Nature, has found evidence that the immune response to Pfizer’s mRNA vaccine against COVID-19 is both strong and potentially long-lasting.
Rutgers Pediatric Infectious Disease Expert Available to Discuss Pfizer’s Vaccine Approved by FDA for Children
Pediatric infectious disease expert David Cennimo is available to discuss the Food and Drug Administration approving Pfizer’s COVID-19 vaccine for emergency use on kids ages 12 to 15. “The Pfizer vaccine had a great track record of safety and success since…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss FDA Preparing to Expand Use of Pfizer’s Coronavirus Vaccine to Adolescents as Young as 12 by Next Week
Stanley H. Weiss, an epidemiologist in infectious and chronic diseases and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health available for media interviews to discuss the FDA preparing to expand use of…
Rutgers Expert Available to Discuss Dangers of Missing Second Doses of COVID-19 Vaccines
Rutgers scholar Stanley H. Weiss is available to discuss the trend of people skipping their second dose of COVID-19 vaccines and how this delays herd immunity. “The second shot leads to a huge boost of the body’s immune protection –…
6 important things to know about your COVID-19 vaccine card
Everyone who gets vaccinated for COVID-19 in the U.S. receives a vaccine card. Sarah Lynch, clinical assistant professor of pharmacy practice at Binghamton University, State University of New York, offers insight into why vaccine cards are important and why you…
FAU Expert Answers Questions about COVID-19 Vaccines
FAU’s Joanna Drowos, D.O., M.P.H., M.B.A., provides answers to some of the most frequently asked questions regarding COVID-19 vaccines.
There is no credible evidence that shows a link between the Pfizer COVID-19 vaccine and infertility
Headlines going viral on Facebook and elsewhere on social media are spreading the claim that the COVID-19 vaccine could lead to infertility in women. There is currently no data to support this claim. Experts weigh in…
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
Israel’s Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.
AACI Applauds Approval of COVID-19 Vaccine, Supports Widespread Vaccination Efforts
The Association of American Cancer Institutes (AACI) commends the U.S. Food and Drug Administration (FDA) for its swift action to grant Emergency Use Authorization (EUA) to Pfizer’s COVID-19 vaccine.
NCCN Announces Research Projects Exploring Axitinib in Various Cancers, in Collaboration with Pfizer
National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.
Rutgers Expert Available to Discuss Rich Countries Hoarding Coronavirus Vaccine
Richard Marlink, director of the Rutgers Global Health Institute, is available to discuss the global health impact of coronavirus vaccine hoarding by rich countries and how such measures may derail worldwide efforts in fighting the pandemic. “Hoarding of vaccines by…
Rutgers Expert Available to Discuss COVID-19 Vaccine Distribution Priorities
Perry N. Halkitis, dean of the Rutgers School of Public Health, is available to discuss the priorities for COVID-19 vaccination distribution. “It is essential that we prioritize vaccinations for healthcare providers and nursing home residents, but they are not the…
UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates
Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.
Geneticist on vaccine race: Beating competition less important than raw numbers early on
MOSCOW (MIPT) — The race for producing and distributing COVID-19 vaccines is accelerating. Following the Pfizer-BioNTech announcement that came two weeks ago, yesterday U.K.-based drugmaker AstraZeneca claimed that its COVID-19 vaccine was 70% effective in trials and could reach 90% efficiency, making…
Rutgers Expert Available to Comment on Pfizer Announcement of Coronavirus Vaccine Efficacy
Reynold Panettieri, Vice Chancellor for Translational Medicine and Science at Rutgers University, is available to discuss the next steps in a vaccine roll-out after Pfizer’s announcement that its coronavirus vaccine was 95 percent effective and had no serious side effects.…
Pfizer, Moderna news is promising, but billions are unlike to get COVID-19 vaccine for years
In just a week, both Moderna and Pfizer have announced that they have developed effective vaccines against COVID-19 — but how long will it be before everyone has access to them? According to Nicole Hassoun, professor of philosophy at Binghamton…
Rutgers Expert Available to Discuss Pfizer’s Vaccine
A Rutgers public health expert is available to discuss Pfizer’s vaccine, which has shown to be effective according to recent clinical results, and the steps we can take to increase public trust when a COVID-19 vaccine is finally approved. “The…
.@umichsph researcher @rmalosh discusses the results of the interim efficacy analysis, shared today by Pfizer and BioNTech, is available to discuss with the media.
Ryan Malosh, assistant research scientist at the University of Michigan School of Public Health, can comment on today’s announcement by Pfizer and BioNTech. His research focuses on vaccine effectiveness, epidemiology and transmission of respiratory viruses, and social determinants of acute…